Discovery of a retigabine derivative that inhibits KCNQ2 potassium channels

Acta Pharmacologica Sinica

Volumn 34, Issue 10, 2013, Pages 1359-1366

  Hu, Hai Ning ^a,b   Zhou, Ping Zheng ^c   Chen, Fei ^a,b   Li, Min ^c   Nan, Fa Jun ^a,b   Gao, Zhao Bing ^c  

^a State Key Laboratory of Drug Research   (China)

^b National Center for Drug Screening   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

CHO cell; HN38; KCNQ2 channel; Retigabine; Structure modification; Whole cell recording; XE991

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; HN 38; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KCNQ; POTASSIUM CHANNEL KCNQ2; RETIGABINE; UNCLASSIFIED DRUG;

ARTICLE; CHO CELL; ELECTROPHYSIOLOGY; FEMALE; IC 50; KINETICS; NONHUMAN; VOLTAGE CLAMP; WHOLE CELL;

ANIMALS; ANTHRACENES; ANTICONVULSANTS; CARBAMATES; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; INHIBITORY CONCENTRATION 50; KCNQ2 POTASSIUM CHANNEL; PATCH-CLAMP TECHNIQUES; PHENYLENEDIAMINES; POTASSIUM CHANNEL BLOCKERS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84887348516     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.79     Document Type: Article

References (14)

1. Brown DA, Passmore GM. Neural KCNQ (Kv7) channels. Br J Pharmacol 2009; 156: 1185-95.
2. Delmas P, Brown DA. Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci 2005; 6: 850-62. (Pubitemid 41568727)
3. Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 2009; 8: 982-1001.
4. Babcock J, Li M. hERG channel function: beyond long QT. Acta Pharmacol Sin 2013; 34: 329-35.
5. Wang H-S, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 1998; 282: 1890-3. (Pubitemid 28555268)
6. Xiong Q, Gao Z, Wang W, Li M. Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds. Trends Pharmacol Sci 2008; 29: 99-107.
7. Yang SP, Yue JM. Discovery of structurally diverse and bioactive compounds from plant resources in China. Acta Pharmacol Sin 2012; 33: 1147-58.
8. + channels with a new gating-modifier. Proc Natl Acad Sci U S A 2010; 107: 15637-42.
9. Pieniaszek HJ Jr, Fiske WD, Saxton TD, Kim YS, Garner DM, Xilinas M, et al. Single-dose pharmacokinetics, safety, and tolerance of linopirdine (DuP 996) in healthy young adults and elderly volunteers. J Clin Pharmacol 1995; 35: 22-30.
10. Zaczek R, Chorvat RJ, Saye JA, Pierdomenico ME, Maciag CM, Logue AR, et al. Two new potent neurotransmitter release enhancers, 10,10-bis(4- pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)- 9(10H)-anthracenone: comparison to linopirdine. J Pharmacol Exp Ther 1998; 285: 724-30. (Pubitemid 28237454)
11. Earl RA, Zaczek R, Teleha CA, Fisher BN, Maciag CM, Marynowski ME, et al. 2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action. J Med Chem 1998; 4: 4615-22. (Pubitemid 28516460)
12. Joshi S, Balan P, Gurney AM. Pulmonary vasoconstrictor action of KCNQ potassium channel blockers. Respir Res 2006; 7: 31.
13. Soh H, Tzingounis AV. The specific slow after hyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels. Mol Pharmacol 2010; 78: 1088-95.
14. Cheung YY, Yu H, Xu K, Zou B, Wu M, McManus OB, et al. Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl) acetamides as novel molecular switches that modulate modes of Kv7.2 (KCNQ2) channel pharmacology: Identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant Kv7.2 channel inhibitor. J Med Chem 2012; 55: 6975-9.